Equities

Aroa Biosurgery Ltd

Aroa Biosurgery Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.63
  • Today's Change0.00 / 0.00%
  • Shares traded106.13k
  • 1 Year change-10.00%
  • Beta1.1687
Data delayed at least 20 minutes, as of Nov 18 2024 04:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in NZD

The 5 analysts offering 12 month price targets for Aroa Biosurgery Ltd have a median target of 1.00, with a high estimate of 1.05 and a low estimate of 0.7134. The median estimate represents a 58.91% increase from the last price of 0.63.
High66.8%1.05
Med58.9%1.00
Low13.2%0.7134

Dividends

Dividend information is not available for Aroa Biosurgery Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in NZD

Aroa Biosurgery Ltd reported annual 2024 losses of -0.018 per share on May 20, 2024.
Average growth rate-209.38%
More ▼

Revenue history & estimates in NZD

Aroa Biosurgery Ltd had revenues for the full year 2024 of 69.07m. This was 12.12% above the prior year's results.
Average growth rate+48.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.